Latest news with #Uppsala
Yahoo
4 days ago
- Business
- Yahoo
Robert Hägg Returns To Sweden
Swedish defenseman Robert Hägg, 30, has signed a one-year contract with Brynäs IF, the Gävle-based SHL club announced on Wednesday. Hägg is returning to Sweden after spending the past 11 seasons in North America, split between the NHL and AHL in six different organizations. 'It feels really good to come to Brynäs,' said Hägg. 'I have been in the USA for many years and felt that it was a good time to return home to Sweden. I have had very good conversations with Johan Alcén and the club has clear visions that match mine. In the end, it was an easy decision when we got to that stage. I look forward to getting to work.' Advertisement 'Robert is a big, solid player who has accumulated a lot of experience and we will benefit greatly from that,' said Alcén, the club's sports director. 'We like his whole aura when he is out on the ice where he does not hesitate to step into the melée. He is a humble and respectful person who really makes his surroundings better and wants to win. He will fit in perfectly with the group.' Born in Uppsala, Sweden, Hägg developed in the MoDo system and he was rumored to be heading to that club a few months ago; however, MoDo's relegation to the second-tier HockeyAllsvenskan was probably a factor in him deciding to play elsewhere. Hägg was chosen in the second round, 41st overall, by the Philadelphia Flyers in the 2013 NHL Entry Draft. Between 2016 and 2025, he played 345 NHL regular-season games for the Flyers, Buffalo Sabres, Florida Panthers, Detroit Red Wings, Anaheim Ducks and Vegas Golden Knights, recording 63 points and 208 penalty minutes. He added three assists in 14 playoff games, all with Philadelphia. Robert Hägg to Anaheim: 'Why did you even sign me at all?' Robert Hägg to Anaheim: 'Why did you even sign me at all?' Last month, while he was still considering his options for the 2024-25 season, Advertisement Robert Hägg gave an interview with a Swedish reporter for where he expressed some of his disappointment with how things worked out in Anaheim. After being a regular NHLer for six seasons, Hägg only played seven games in the league over the past two seasons. He considered returning to Sweden last summer after a particularly sour experience in Anaheim, which he shared with Swedish media, but decided to give it one more shot with Vegas. Hägg joins a Brynäs team that is coming off a season in which it shattered all expectations. Just after being promoted from the HockeyAllsvenskan, Brynäs finished first overall in the regular season and made it to the SHL finals, where it lost to Lulea in six games. In addition to Hägg, the club's roster includes ex-NHLers Jakob Silfverberg, Johan Larsson, Oskar Lindblom, Christian Djoos, Axel Jonsson-Fjällby, Mattias Norlinder and goaltender Erik Källgren. Last year's team included defensemen Charles-Édouard D'Astous and Victor Söderström – however, D'Astous has signed with the Tampa Bay Lightning and, although Söderström is under contract for another season with Brynäs, it is expected that he might sign with the Chicago Blackhawks – who acquired his NHL rights in the spring. Advertisement Photo © Eric Hartline-Imagn Images Victor Soderstrom Wins Borje Salming Trophy As SHL's Top Defenseman Victor Soderstrom Wins Borje Salming Trophy As SHL's Top Defenseman Victor Söderström has been named the top defenseman in the Swedish Hockey League for the 2024-25 season. As a result, he has been awarded the Börje Salming Trophy.
Medical News Today
26-05-2025
- Health
- Medical News Today
Heart health: Exercise not enough to offset effects of poor sleep
Poor sleep can impact health in many ways, particularly the heart. blackCAT/Getty Images A study led by researchers from Uppsala University examined how sleeping poorly can affect the body — specifically heart health. In the crossover study, scientists checked the participants' biomarkers after they underwent sessions of poor sleep and healthy sleep. They found that biomarkers associated with inflammation and heart health increased after just three nights of poor sleep. While the Centers for Disease Control and Prevention recommend that adults get at least seven hours of sleep per night, this can sometimes be tough to achieve. Whether it is due to stress or underlying health issues, it is almost inevitable to get less than the recommended sleep at some point. A new study examines how quickly the body can start reacting negatively to poor sleep. The results show that getting a bad night's sleep just three nights in a row can start affecting health. When seeing whether exercise could offset the effects of three nights of poor sleep, the researchers learned that it could help but did not cancel the effects of poor sleep. The study appears in the journal Biomarker Research . The researchers noted that prior studies have shown the cardiovascular risks of chronic poor sleep. However, they thought research on short-term sleep deprivation and physiological factors needed to be expanded. This study examined the effects of poor sleep in 16 young men , who the researchers noted all had healthy weights. The researchers carried out the study over two sessions, each of which included three nights of monitoring in a sleep lab. In one session, the men underwent 3 nights of restricted sleep. On these nights, they only got around 4.25 hours of sleep. The researchers collected blood samples from the participants in the morning and evening and before and after high-intensity exercise. The high-intensity exercise sessions lasted 30 minutes each. In another 3-night session, the participants got a normal night's sleep of around 8.5 hours on average. The study analyzed 88 proteins related to cardiovascular disease, such as leptin, lipoprotein lipase, and galectin-9. After reviewing the data collected, the researchers found that short-term sleep restriction was enough to change the participants' biomarkers. Just three nights of poor sleep elevated proteins that are associated with an increased risk of cardiovascular disease. Exercise was not enough to completely cancel out the harm caused by sleep restriction. While exercise did impact protein levels to some degree, the participants still experienced increases in 16 proteins related to cardiovascular disease. According to the study authors, 'the upregulated set included several stress, interleukin, and chemokine-related proteins.' Some beneficial proteins that are connected to the positive effects of exercise, such as IL-6 and BDNF, were elevated regardless of sleep status. However, the proteins in people with sleep restriction were not elevated as much as in people with normal sleep. The study shows that short-term sleep restriction can contribute to biological changes even in young, healthy men. This information demonstrates the need for awareness of how just a few nights of poor sleep have the potential to impact the heart. The study authors emphasized that more research is necessary to determine the impacts that short-term sleep restriction can have on older adults and women. Cheng-Han Chen, MD, a board certified interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center, spoke with Medical News Today about the study findings. 'This biomarker-based study found changes in blood chemistry associated with inflammation after a few nights of sleep restriction,' said Chen. 'This suggests a biochemical mechanism by which poor quality sleep can impact someone's health.' Chen said the results are 'not entirely surprising' and noted that poor sleep can impact numerous health factors. In addition to cardiovascular health, Chen said sleep restriction can negatively impact endocrine and immune functioning. For people who want to improve their sleep quality and reduce the chances of activating harmful proteins related to sleep restriction, Chen suggested that people maintain 'a consistent sleep schedule and bedtime routine.' 'We also recommend that people practice good sleep 'hygiene' including avoiding caffeine and alcohol later in the day, avoiding the use of electronic devices before bedtime, limiting long daytime naps, exercising regularly, and following a healthy diet,' Chen told MNT . Harneet Walia, MD, medical director of sleep for Miami Cardiac & Vascular Institute, part of Baptist Health South Florida, also spoke with MNT . Walia noted the 'robust methods' used in the study and said, 'the findings add meaningful evidence to the growing literature suggesting that sleep duration directly impacts cardiovascular health.' 'This adds to the body of literature and amplifies the association of sleep restriction with a pro-inflammatory state, suggesting that even short-term sleep restriction can have significant health consequences.' — Harneet Walia, MD Walia recommended that people 'create a relaxing bedtime routine to signal to your body it's time to wind down' to ensure the best chances for a good night's sleep. Heart Disease Cardiovascular / Cardiology Sleep / Sleep Disorders / Insomnia
The Independent
23-05-2025
- Health
- The Independent
Scientists pinpoint how many hours sleep will increase your risk of heart disease
We've long known that a lack of sleep is bad for the heart – but scientists are now starting to understand exactly how it causes harm. In a new study from Uppsala University in Sweden, researchers found that just three nights of restricted sleep – around four hours a night – triggered changes in the blood linked to a higher risk of heart disease. The researchers looked at inflammatory proteins in the blood. These are molecules the body produces when it is under stress or fighting off illness. When these proteins stay high for a long time, they can damage blood vessels and raise the risk of problems like heart failure, coronary heart disease and atrial fibrillation (irregular heartbeat). The study involved 16 healthy young men who spent several days in a lab, where everything from their meals to their activity levels and light exposure was carefully controlled. The participants followed two routines: three nights of normal sleep (8.5 hours) and three night of sleep restriction (4.25 hours). After each sleep phase, the men completed a short, high-intensity cycling workout, and their blood was tested before and after. Researchers measured almost 90 different proteins in the blood samples. They found that sleep deprivation caused a clear rise in inflammatory markers linked to heart disease. And while exercise usually boosts healthy proteins such as interleukin-6 and BDNF (which support brain and heart health), these responses were weaker after poor sleep. Even young adults Strikingly, the changes happened even in young, healthy adults, and after only a few nights of bad sleep. That's worrying given how common it is for adults to experience poor sleep from time to time – and around one in four people work shifts that disrupt sleep patterns. The researchers also discovered that the time of day blood was taken mattered: protein levels varied between morning and evening, and even more so when sleep was restricted. This suggests that sleep affects not only what's in your blood, but when those changes are most visible. Although modern life often encourages us to trade sleep for productivity, socialising or screen time, studies like this remind us that the body keeps score – quietly, chemically and without compromise. Annie Curtis is a Professor (Assoc) in the School of Pharmacy and Biomolecular Sciences (PBS) at RCSI University of Medicine and Health Sciences.
Yahoo
23-05-2025
- Business
- Yahoo
New DiviTum(R) TKa Data to be Presented at ASCO in Three Cancer Types
UPPSALA, SE / / May 23, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest cancer meeting, the American Society of Clinical Oncology (ASCO), May 30 - June 3, 2025. ASCO is the world's largest and most influential oncology conference, bringing together approximately 31,000 oncology professionals. The new data further validates DiviTum TKa as a predictive biomarker across three cancer indications: Hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients treated with CDK4/6 inhibitors in the high-profile PEARL study BRAF V600-mutated metastatic melanoma treated with Immune Checkpoint Inhibitors (ICI) Ovarian cancer treated with platinum-based chemotherapy While the PEARL study represents a large-scale trial that addresses a key clinical decision-making challenge in MBC - whether to select newer versus established treatment combinations - the studies in melanoma and ovarian cancer are more exploratory in nature. " It is exciting that DiviTum TKa will be presented to such a large audience as a predictive biomarker for personalized treatment selection in MBC, malignant melanoma , and ovarian cancer, thereby significantly extending the number of patients who can benefit from DiviTum TKa. Equally exciting, that DiviTum TKa can also predict outcomes for patients receiving the new generation Immune Checkpoint Inhibitors for malignant melanoma," said Anders Rylander, CEO of Biovica. Thank you to the long list of partners in eight European countries, who have contributed to bringing about new knowledge. More about the Abstract Title Institution Patient Population Key Findings "Thymidine kinase activity (TKa) as independent predictor of outcome in metastatic breast cancer (MBC) patients in theGEICAM/2013-02 PEARL trial: A predictive biomarker for personalized treatment selection between Capecitabine vs ET + Palbociclib in MBC" GEICAM, Spain Treatment for HR+/HER2- metastatic breast cancer (MBC) with early (≤12 months) progression. TKa can predict for personalized treatment selection between Capecitabine vs ET + Palbociclib CT vs a CDK4/6 inhibitor influence TKa response differently, and the direction and magnitude of the TKa response can predict for benefit to a specific original PEARL study analysis showed no outcome differences between Cape vs ET + Palbo in HR+/HER2- MBC pts, however assessment of TKa before and during therapy identified which patients had the highest probability of responding. "Serum Thymidine Kinase Activity (TKa) as a Potential Biomarker in the Sequential Immunotherapy and Targeted Therapy for Metastatic BRAF V600 Mutated Melanoma (SECOMBIT) trial" 30 centers in: Austria, France Greece, Italy, Spain, Sweden, and Switzerland BRAF V600 mutatedmetastatic melanoma TKa can predict patient outcome inBRAF V600 mutated metastatic melanomaPatients with elevated TKa is an evident poor prognosis study to evaluate the role of TKa as a biomarker in a prospective clinical trial in patients with metastatic melanoma. "Thymidine kinase activity as a prognostic and predictive tool in blood samples from primary ovarian cancer patients" University of Duisburg-Essen, Germany Ovarian Cancer Baseline TKa levels in both serum and plasma significantly correlated with OS and DFS, which identifies circulating TKa as a promising prognostic marker in OC. It might further serve as a predictive marker for response to platinum-based chemotherapy. However, prospective validation of these results is needed in order to further specify the clinical value of TKa. List of abbreviationsBC Breast CancerBL Base Line - prior to treatmentBRAF V600 BRAF is a human gene responsible for producing the protein B-Raf, which is involved in signaling direct cell growth. The V600E mutation describes an amino acid substitution at position 600 in BRAF from a valine (V) to a glutamic acid (E)CDK4/6i CDK4/6 inhibitor treatmentsDFS Disease-Free SurvivalHER2 Human Epidermal Growth Factor Receptor 2HR Hormone receptorHR+ Hormone receptor-positiveMBC Metastatic Breast CancerOS Overall SurvivalPts PatientsTKa Thymidine Kinase activity Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments New DiviTum® TKa data to be presented at ASCO in three cancer types SOURCE: Biovica International View the original press release on ACCESS Newswire
Yahoo
23-05-2025
- Business
- Yahoo
New DiviTum(R) TKa Data to be Presented at ASCO in Three Cancer Types
UPPSALA, SE / / May 23, 2025 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, active in cancer monitoring, today announces that three abstracts based on studies using the blood test DiviTum TKa will be presented at the world's largest cancer meeting, the American Society of Clinical Oncology (ASCO), May 30 - June 3, 2025. ASCO is the world's largest and most influential oncology conference, bringing together approximately 31,000 oncology professionals. The new data further validates DiviTum TKa as a predictive biomarker across three cancer indications: Hormone receptor-positive (HR+) metastatic breast cancer (MBC) patients treated with CDK4/6 inhibitors in the high-profile PEARL study BRAF V600-mutated metastatic melanoma treated with Immune Checkpoint Inhibitors (ICI) Ovarian cancer treated with platinum-based chemotherapy While the PEARL study represents a large-scale trial that addresses a key clinical decision-making challenge in MBC - whether to select newer versus established treatment combinations - the studies in melanoma and ovarian cancer are more exploratory in nature. " It is exciting that DiviTum TKa will be presented to such a large audience as a predictive biomarker for personalized treatment selection in MBC, malignant melanoma , and ovarian cancer, thereby significantly extending the number of patients who can benefit from DiviTum TKa. Equally exciting, that DiviTum TKa can also predict outcomes for patients receiving the new generation Immune Checkpoint Inhibitors for malignant melanoma," said Anders Rylander, CEO of Biovica. Thank you to the long list of partners in eight European countries, who have contributed to bringing about new knowledge. More about the Abstract Title Institution Patient Population Key Findings "Thymidine kinase activity (TKa) as independent predictor of outcome in metastatic breast cancer (MBC) patients in theGEICAM/2013-02 PEARL trial: A predictive biomarker for personalized treatment selection between Capecitabine vs ET + Palbociclib in MBC" GEICAM, Spain Treatment for HR+/HER2- metastatic breast cancer (MBC) with early (≤12 months) progression. TKa can predict for personalized treatment selection between Capecitabine vs ET + Palbociclib CT vs a CDK4/6 inhibitor influence TKa response differently, and the direction and magnitude of the TKa response can predict for benefit to a specific original PEARL study analysis showed no outcome differences between Cape vs ET + Palbo in HR+/HER2- MBC pts, however assessment of TKa before and during therapy identified which patients had the highest probability of responding. "Serum Thymidine Kinase Activity (TKa) as a Potential Biomarker in the Sequential Immunotherapy and Targeted Therapy for Metastatic BRAF V600 Mutated Melanoma (SECOMBIT) trial" 30 centers in: Austria, France Greece, Italy, Spain, Sweden, and Switzerland BRAF V600 mutatedmetastatic melanoma TKa can predict patient outcome inBRAF V600 mutated metastatic melanomaPatients with elevated TKa is an evident poor prognosis study to evaluate the role of TKa as a biomarker in a prospective clinical trial in patients with metastatic melanoma. "Thymidine kinase activity as a prognostic and predictive tool in blood samples from primary ovarian cancer patients" University of Duisburg-Essen, Germany Ovarian Cancer Baseline TKa levels in both serum and plasma significantly correlated with OS and DFS, which identifies circulating TKa as a promising prognostic marker in OC. It might further serve as a predictive marker for response to platinum-based chemotherapy. However, prospective validation of these results is needed in order to further specify the clinical value of TKa. List of abbreviationsBC Breast CancerBL Base Line - prior to treatmentBRAF V600 BRAF is a human gene responsible for producing the protein B-Raf, which is involved in signaling direct cell growth. The V600E mutation describes an amino acid substitution at position 600 in BRAF from a valine (V) to a glutamic acid (E)CDK4/6i CDK4/6 inhibitor treatmentsDFS Disease-Free SurvivalHER2 Human Epidermal Growth Factor Receptor 2HR Hormone receptorHR+ Hormone receptor-positiveMBC Metastatic Breast CancerOS Overall SurvivalPts PatientsTKa Thymidine Kinase activity Contact Anders Rylander, CEOPhone: +46 76 666 16 47E-mail: Anders Morén, CFOPhone: +46 73 125 92 46E-mail: Biovica - Treatment decisions with greater confidence Biovica develops and commercializes blood-based biomarker assays that help oncologists monitor cancer progression. Biovica's assay, DiviTum® TKa, measures cell proliferation by detecting the TKa biomarker in the bloodstream. The assay has demonstrated its ability to provide insight to therapy effectiveness in several clinical trials. The first application for the DiviTum® TKa test is treatment monitoring of patients with metastatic breast cancer. Biovica's vision is: "Improved care for cancer patients." Biovica collaborates with world-leading cancer institutes and pharmaceutical companies. DiviTum® TKa has received FDA 510(k) clearance in the US and is CE-marked in the EU. Biovica's shares are traded on the Nasdaq First North Premier Growth Market (BIOVIC B). FNCA Sweden AB is the company's Certified Adviser. For more information, please visit: Attachments New DiviTum® TKa data to be presented at ASCO in three cancer types SOURCE: Biovica International View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
